Latest On Brickell Biotech, Inc (BBI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-09-07 14:50 EST | News | Brickell Biotech changes name to Fresh Tracks Therapeutics | N/A |  |
| 2022-08-11 23:27 EST | News | Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M | N/A | |
| 2022-08-11 23:27 EST | News | Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-11 06:32 EST | News | Brickell Biotech Q2 2022 Earnings Preview | N/A | |
| 2022-07-20 19:03 EST | News | Brickell Biotech regains Nasdaq compliance for minimum bid price requirement | N/A | |
About Brickell Biotech, Inc (BBI):
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.
General
- Name Brickell Biotech, Inc
- Symbol BBI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 13
- Last Split Factor1:7
- Last Split Date2019-09-03
- Fiscal Year EndDecember
- IPO Date1993-03-15
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.brickellbio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 6.93
- Price/Book (Most Recent Quarter) 3.4
- Enterprise Value Revenue 17.87
- Enterprise Value EBITDA 0.04
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.44
- Next Year EPS Estimate -$0.38
- Next Quarter EPS Estimate -$0.10
- Operating Margin -1151%
- Return on Assets -51%
- Return on Equity -121%
- Revenue 1.82 million
- Earnings Per Share -$9.55
- Revenue Per Share $0.07
- Gross Profit -9394000
- Quarterly Earnings Growth -96%
Highlights
- Market Capitalization 82.99 million
- EBITDA -13430000
- PE Ratio -0.23
- Analyst Target Price $5.5
- Book Value Per Share $2.33
Share Statistics
- Shares Outstanding 66.93 million
- Shares Float 65.62 million
- % Held by Insiders 208%
- % Held by Institutions 10.65%
- Shares Short 4.58 million
- Shares Short Prior Month 4.61 million
- Short Ratio 1.12
- Short % of Float 9%
- Short % of Shares Outstanding 9%
Technicals
- 52 Week High $2.61
- 52 Week Low $0.47
- 50 Day Moving Average 1.27
- 200 Day Moving Average 0.92
Dividends
- Dividend Date 2019-09-03
- ExDividend Date N/A
- Dividend Yield 0%
Brickell Biotech, Inc (BBI) Dividend Calendar:
BBI's last dividend payment was made to shareholders on September 3, 2019.
Brickell Biotech, Inc (BBI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Brickell Biotech, Inc (BBI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Brickell Biotech, Inc (BBI) Chart:
Brickell Biotech, Inc (BBI) News:
Below you will find a list of latest news for Brickell Biotech, Inc (BBI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Brickell Biotech, Inc (BBI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest BBI Trades:
Brickell Biotech, Inc (BBI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-23 | 8-K (Current report) | |
| 2020-10-23 | 424B4 (Prospectus [Rule 424(b)(4)]) | |
| 2020-10-22 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-22 | EFFECT (Notice of Effectiveness) | |
| 2020-10-19 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-13 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-09-25 | 8-K (Current report) | |
| 2020-09-24 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-09-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-09 | S-8 (Securities to be offered to employees in employee benefit plans) | |
Brickell Biotech, Inc (BBI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Brickell Biotech, Inc (BBI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 208%
Institutional Ownership: 1065%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-18 | David R. McAvoy | General Counsel and CCO | Buy | 6,000.00 | 0.84 | 5,038.80 | 6,000.00 | |
| 2020-09-18 | David R. McAvoy | General Counsel and CCO | Buy | 16,526.00 | 0.83 | 13,713.27 | 75,883.00 | |
| 2020-09-16 | DENNISON T VERU | Director | Buy | 14,645.00 | 0.80 | 11,758.47 | 50,810.00 | |
| 2020-09-15 | REGINALD L HARDY | Chairman of the Board | Buy | 15,226.00 | 0.81 | 12,333.06 | 205,849.00 | |
| 2020-09-15 | DENNISON T VERU | Director | Buy | 13,580.00 | 0.81 | 10,999.80 | 20,810.00 | |
| 2020-09-15 | VIJAY B SAMANT | Director | Buy | 10,493.00 | 0.81 | 8,499.33 | 23,542.00 | |
| 2020-09-15 | GARY A LYONS | Director | Buy | 11,934.00 | 0.81 | 9,666.54 | 24,729.00 | |
| 2020-09-15 | DENNISON T VERU | Director | Buy | 15,355.00 | 0.81 | 12,416.05 | 36,165.00 | |
| 2020-08-31 | VIJAY B SAMANT | Director | Buy | 609.00 | 19,680.00 | | ||
| 2020-08-31 | REGINALD L HARDY | Chairman of the Board | Buy | 883.00 | 197,954.00 | | ||
| 2020-08-31 | GARY A LYONS | Director | Buy | 692.00 | 21,772.00 | | ||
| 2020-08-31 | DENNISON T VERU | Director | Buy | 788.00 | 960,388.00 | | ||
| 2020-07-31 | VIJAY B SAMANT | Director | Buy | 608.00 | 19,327.00 | | ||
| 2020-07-31 | REGINALD L HARDY | Chairman of the Board | Buy | 882.00 | 197,354.00 | | ||
| 2020-07-31 | GARY A LYONS | Director | Buy | 692.00 | 21,426.00 | | ||
| 2020-07-31 | DENNISON T VERU | Director | Buy | 787.00 | 959,600.00 | | ||
| 2020-06-30 | VIJAY B SAMANT | Director | Buy | 608.00 | 18,975.00 | | ||
| 2020-06-30 | REGINALD L HARDY | Chairman of the Board | Buy | 883.00 | 196,755.00 | | ||
| 2020-06-30 | GARY A LYONS | Director | Buy | 691.00 | 21,080.00 | | ||
| 2020-06-30 | DENNISON T VERU | Director | Buy | 787.00 | 958,813.00 | |